Summary by Moomoo AI
WuXi Biologics (Cayman) Inc. submitted the latest monthly report on securities changes to the Hong Kong Exchange and Clearing Limited on October 4, 2024, reporting the shareholding changes as of September 30, 2024. The report shows that the company's statutory/registered share capital remains unchanged at a total of $50,000 with a par value of USD1/120,000 per share. As for the issued shares, the month-end balance is 4,154,337,515 ordinary shares, an increase of 1,008,159 shares from the previous month. This increase mainly comes from the exercise of stock options, including multiple pre-IPO stock purchase rights plans, with a total amount of $362,936.89 raised from the exercise of options within the month. In addition, the shares repurchased by the company in June 2024 and planned for cancellation have not been canceled within the reporting period, involving 46,230,500 shares. According to the report, all securities issuance or sale/transfers of treasury shares have obtained formal approval from the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements.
